The Infectious Diseases Society of America (IDSA) issued the 2025 practice guideline addressing the use of vaccines for prevention of seasonal COVID-19, influenza, and RSV infections specifically in immunocompromised patients. The guideline is indexed on PubMed as a Practice Guideline and appears as a free article in Clinical Infectious Diseases.
The PubMed entry identifies the work as an official guideline document authored by a multidisciplinary group of clinicians and experts. The record provided here contains bibliographic and authorship information but does not include the guideline text or abstract in the excerpt available for this task.
According to the article title and PubMed indexing, the guideline focuses on vaccines for prevention of seasonal respiratory viral infections—COVID-19, influenza, and respiratory syncytial virus (RSV)—in patients who are immunocompromised. The PubMed record does not supply the guideline’s detailed scope statements, inclusion or exclusion criteria for patient groups, or explicit definitions of the immunocompromised populations addressed.
Because the source excerpt lacks the guideline body or abstract, specific clinical details such as recommended vaccine formulations, dosing schedules, timing relative to immunosuppressive therapies, contraindications, or evidence grading were not reported in the provided source.
The guideline lists multiple named authors with affiliations across US academic medical centers and IDSA clinical affairs. Lead and contributing authors include Anoma Nellore and coauthors representing diverse divisions and specialties, including transplant programs, pediatric infectious diseases, oncology infectious diseases, and general infectious diseases.
Affiliated institutions named in the PubMed record include:
The presence of authors from transplant, pediatric, oncology, and general infectious disease services indicates multidisciplinary input, but the PubMed entry does not specify author roles, conflicts of interest in the excerpt shown here, or the guideline development process steps.
The PubMed record provides the following bibliographic citation:
The article is listed as a free article on PubMed, and full-text access is available via the journal platform link provided in the record.
The PubMed entry includes a full-text link (via the journal platform) and marks the article as a free article. Users seeking the guideline content, detailed recommendations, evidence summaries, and implementation guidance should access the full text through the provided journal link or the IDSA website if available.
The PubMed record also provides tools for citation export, saving to collections, and linking out to related resources; those features are part of the PubMed interface rather than the guideline content itself.
The excerpt of the PubMed record used as the source for this rewrite contains bibliographic metadata, author and affiliation listings, and publication identifiers but does not include the guideline’s abstract or the guideline text. Consequently, the following were not reported in the provided source and therefore cannot be restated here:
Where the guideline content is needed for clinical decision-making, clinicians should consult the full-text guideline and supporting materials cited in the journal article.
Recommended bibliographic details from the PubMed record are:
Anoma Nellore et al. IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19, Influenza, and RSV Infections in Immunocompromised Patients. Clin Infect Dis. 2026 Aug 24;82(Supplement_3):i105-i110. doi: 10.1093/cid/ciag114. PMID: 41766454.
If further details or the text of specific recommendations are required, consult the Clin Infect Dis full-text link provided in the PubMed record or the IDSA Clinical Affairs and Practice Guidelines resources.